Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + pomalidomide (RP) in previously untreated indolent B‑cell lymphoma
ChiCTR2500106326Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and pomalidomide in mature B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and 1 more, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
rituximabpomalidomide
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)Indolent B-cell lymphoproliferative disorder (iBCLPD)
Beyond the preview
Go deeper on ChiCTR2500106326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106326.